The Cost-Effectiveness of Preventing Cytomegalovirus Disease in AIDS Patients

References

• Aboulker J. , Swart A. Preliminary analysis of the concorde trial. The Lancet (1993) 341 8849 889 890 Crossref, Google Scholar
• (1994) (National Technical Information Service, Springfield, Virginia) . AIDS Cost and Services Utilization Survey, Public use tapes #4 and #5 (PB94-189891) Google Scholar
• Arno P. S. , Shenson D. , Siegel N. F. , Franks P. , Lee P. R. Economic and policy implications of early intervention in HIV disease. JAMA (1989) 262 11 1493 1498 Crossref, Google Scholar
• Balfour H. H. Management of cytomegalovirus disease with antiviral drugs. Rev. Infectious Diseases (1990) 12 Suppl. 7 S849 S860 Crossref, Google Scholar
• Brosgart C. , Craig C. , Hillman D. , Louis T. A. , Alston B. , Fisher E. , El-Sadr W. Final results from a randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of CMV retinal and gastrointestinal mucosal disease. 11th Internat. Conf. AIDS (1996) Vancouver, Canada . Presentation Th.B.301 Google Scholar
• Carpenter C. C. J. , Fischl M. A. , Hammer S. M. , Hirsch M. S. , Jacobsen D. M. , Katzenstein D. A. , Montaner J. S. , Richman D. D. , Saag M. S. , Schooley R. T. , Thompson M. A. , Vella S. , Yeni P. G. , Volberding P. A. Antiretroviral therapy for HIV infection in 1996, recommendations of an international panel. JAMA (1996) 276 2 146 154 Crossref, Google Scholar
• Castellano A. R. , Nettleman M. D. Cost and benefit of secondary prophylaxis for Pneumocystis carinii pneumonia. JAMA (1991) 266 6 820 824 Crossref, Google Scholar
• Centers for Disease Control and Prevention USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: A summary. Morbidity and Mortality Weekly Report (1995) 44 RR-8, July 14 1 35 Google Scholar
• Drug Topics Red Book Medical Economics (1996) (Montvale, New Jersey) Google Scholar
• Drummond M. F. , Torrance G. W. , Mason J. Cost-effectiveness league tables: More harm than good? Soc. Sci. Medicine (1993) 37 1 33 40 Crossref, Google Scholar
• Enger C. , Graham N. , Peng Y. , Chmiel J. S. , Kingsley L. A. , Detels R. , Munoz A. Survival from early, intermediate, and late stages of HIV infection. JAMA (1996) 275 17 1329 1334 Crossref, Google Scholar
• Fischl M. A. , Richman D. D. , Grieco M. H. AIDS Clinical Trials Group The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. New England J. Medicine (1987) 317 4 185 191 Crossref, Google Scholar
• Fischl M. A. , Richman D. D. , Hansen N. the AZT Collaborative Working Group The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann. Internal Medicine (1990) 112 10 727 737 Crossref, Google Scholar
• Freedberg K. A. , Tosteson A. N. A. , Cohen C. J. , Cotton D. J. Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected persons with CD4 counts below 200/mm3: A cost-effectiveness analysis. J. Acquired Immune Deficiency Syndromes (1991) 4 5 521 531 Google Scholar
• Gold M. R. , Siegel J. E. , Russel L. B. , Weinstein M. C. Cost-effectiveness in Health and Medicine, Report of the Panel on Cost-effectiveness in Health and Medicine (1996) (Oxford University Press, New York) Google Scholar
• Graham N. , Zeger S. , Park L. , Vermund S. , Detels R. , Rinaldo C. , Phair J. The effects on survival of early treatment of HIV infection. New England J. Medicine (1992) 326 16 1037 1042 Crossref, Google Scholar
• Harris J. E. Improved short-term survival of AIDS patients initially diagnosed with Pneumocystis carinii pneumonia, 1984 through 1987. JAMA (1990) 263 3 397 401 Crossref, Google Scholar
• Hellinger F. J. Forecasts of the costs of medical care for persons with HIV: 1992–1995. Inquiry (1992) 29 3 356 365 Google Scholar
• Hellinger F. J. The lifetime cost of treating a person with HIV. JAMA (1993) 270 4 474 478 Crossref, Google Scholar
• Hellinger F. J. , Fleishman J. A. , Hsia D. C. AIDS treatment costs during the last months of life: Evidence from the ACSUS. Health Services Res. (1994) 29 5 569 581 Google Scholar
• Hirsch M. S. Cytomegalovirus and its role in the pathogenesis of acquired immunodeficiency syndrome. Transplantation Proc. (1991) 23 Suppl. 3 118 121 Google Scholar
• Holtgrave D. R. , Qualls N. L. Threshold analysis and programs for prevention of HIV infection. Medical Decision Making (1995) 15 4 311 317 Crossref, Google Scholar
• Hoover D. R. , Saah A. J. , Bacellar H. , Phair J. , Detels R. , Anderson R. , Kaslow R. A. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS cohort study. New England J. Medicine (1993) 329 26 1922 1926 Crossref, Google Scholar
• Kaplan R. M. , Bush J. W. Health-related quality of life measurement for evaluation research and policy analysis. Health Psych. (1981) 1 1 61 80 Crossref, Google Scholar
• Laird N. M. , Ware J. H. Random effects model for longitudinal data. Biometrics (1982) 38 4 963 974 Crossref, Google Scholar
• Laupacis A. , Feeny D. , Detsky A. , Tugwell P. X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. J. Canadian Medical Assoc. (1992) 146 4 473 481 Google Scholar
• Lemp G. F. , Payne S. F. , Neal D. , Temelso T. , Rutherford G. W. Survival trends for patients with AIDS. JAMA (1990) 263 3 402 406 Crossref, Google Scholar
• Mason J. , Drummond M. F. , Torrance G. W. Some guidelines on the use of cost-effectiveness league tables. British Medical J. (1993) 306 6877 570 572 Crossref, Google Scholar
• McCarthy B. , Wong J. , Munoz A. , Sonnenberg F. Who should be screened for HIV infection? Arch. Internal Medicine (1993) 153 9 1107 1116 Crossref, Google Scholar
• McGinley L. States move to ration promising AIDS drugs. The Wall Street Journal (1996) August 22 B1 Google Scholar
• McGinnis J. M. , Foege W. H. Actual causes of death in the United States. JAMA (1993) 270 18 2207 2212 Crossref, Google Scholar
• Merigan T. C. Treatment of cytomegalovirus infection in the AIDS patient. Transplantation Proc. (1991) 23 Suppl. 3 122 125 Google Scholar
• Merigan T. C. , Resta S. Cytomegalovirus: Where have we been and where are we going? Rev. Infectious Diseases (1990) 12 Suppl. 7 S693 S700 Crossref, Google Scholar
• Miller D. K. , Homan S. M. Determining transition probabilities. Medical Decision Making (1994) 14 1 52 58 Crossref, Google Scholar
• Moore R. D. , Hidalgo J. , Sugland B. W. , Chaisson R. E. Zidovudine and the natural history of the acquired immunodeficiency syndrome. New England J. Medicine (1991) 324 20 1412 1416 Crossref, Google Scholar
• Moore R. D. , Chaisson R. E. Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS. AIDS (1995) 9 12 1337 1342 Crossref, Google Scholar
• Moore R. D. , Bartlett J. G. Combination antiviral therapy in HIV infection: An economic perspective. PharmacoEconomics (1996) 10 2 109 113 Crossref, Google Scholar
• Multicenter AIDS Cohort Study (MACS) (1995) . Public data set (release PO4), National Technical Information Service, Springfield, Virginia Google Scholar
• National Alliance of State and Territorial AIDS Directors The fiscal status of AIDS drug assistance programs: Findings from a January 1996 national survey of state AIDS directors. (1996) . Prepared for the United States Health Resources and Services Administration, Division of HIV Services (April) Google Scholar
• Owens D. K. , Nease R. F. , Harris R. A. Use of cost-effectiveness and value of information analyses to customize guidelines for specific clinical practice settings. Medical Decision Making (1993) 13 4 395 . (abstract) Google Scholar
• Owens D. K. , Nease R. F. , Harris R. A. Cost-effectiveness of HIV screening in acute care settings. Arch. Internal Medicine (1996) 156 4 394 404 Crossref, Google Scholar
• Paltiel A. D. , Stinnett A. A. , Spilker B. AIDS. Quality of Life and Pharmacoeconomics in Clinical Trials (1996) 2nd ed. (Raven Press, New York) Google Scholar
• Pear R. Expense means many can't get drugs for AIDS. The New York Times (1997) February 16 A1 Google Scholar
• Pertel P. , Hirschtick R. , Phair J. , Chmiel J. , Poggensee L. , Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J. Acquired Immune Deficiency Syndromes (1992) 5 11 1069 1074 Google Scholar
• Phair J. , Munoz A. , Detels R. , Kaslow R. , Rinaldo C. , Saah A. the Multicenter AIDS Cohort Study Group The risk of Pneumocystis carinii pneumonia among men infected with HIV Type I. Multicenter AIDS cohort study group. New England J. Medicine (1990) 322 3 161 165 Crossref, Google Scholar
• Pierce M. , Crampton S. , Henry D. , Heifets L. , LaMarca A. , Montecalvo M. , Wormser G. P. , Jablonowski H. , Jemsek J. , Cynamon M. , Yangco B. G. , Notario G. , Craft J. C. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. New England J. Medicine (1996) 335 6 384 391 Crossref, Google Scholar
• Polis M. A. , deSmet M. D. , Baird B. F. , Mellow S. , Falloon J. , Davey R. T. , Kovacs J. A. , Palestine A. G. , Nussenblatt R. B. , Masur H. Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). Amer. J. Medicine (1993) 94 2 175 180 Crossref, Google Scholar
• Robbins G. K. , Cotton D. J. Cost-effectiveness of ganciclovir for prevention of CMV retinitis. Fourth Conference on Retroviruses and Opportunistic Infections (1997) Washington, DC . Abstract 296, Session 31 Google Scholar
• Rose D. N. , Sacks H. S. , Lan V. Cost-effectiveness of oral ganciclovir to prevent cytomegalovirus disease in patients with AIDS. 11th Internat. Conf. AIDS (1996) Vancouver, Canada . Presentation Th.B.303 Google Scholar
• Sande M. A. , Carpenter C. C. , Cobbs C. G. , Holmes K. K. , Sanford J. P. Antiretroviral therapy for adult HIV-infected patients: Recommendations from a state-of-theart conference. JAMA (1993) 270 21 2583 2589 Crossref, Google Scholar
• Schooley R. T. Cytomegalovirus in the setting of infection with human immunodeficiency virus. Rev. Infectious Diseases (1990) 12 Suppl. 7 S811 S819 Crossref, Google Scholar
• Scitovsky A. A. , Rice D. P. Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991. Public Health Rep. (1987) 102 1 5 17 Google Scholar
• Seage G. , Oddleifson S. , Carr E. , Shea B. , Makareqicz-Robert L. , Beuzekom M. , De Maria A. Survival with AIDS in Massachusetts 1979–1989. Amer. J. Public Health (1993) 83 1 72 78 Crossref, Google Scholar
• Seage G. R. , Landers S. , Barry M. A. , Groopman J. , Lamb G. , Epstein A. Medical care costs of AIDS in Massachusetts. JAMA (1986) 256 22 3107 3109 Crossref, Google Scholar
• Spector S. A. , Pilcher M. , Lamy P. , Hsia K. , Wong R. , Stempien M. J. Roche Cooperative Oral Ganciclovir Study Group PCR of plasma for cytomegalovirus DNA identifies HIV-infected persons most likely to benefit from oral ganciclovir prophylaxis. 11th Internat. Conf. AIDS (1996) Vancouver, Canada . Presentation Th.B.302 Google Scholar
• Spector S. A. , McKinley G. F. , Lalezari J. P. , Samo T. , Andruczk R. , Follansbee S. , Sparti P. D. , Havlir D. V. , Simpson G. , Buhles W. , Wong R. , Stempien M. Roche Cooperative Oral Ganciclovir Study Group Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. New England J. Medicine (1996) 334 23 1491 1497 Crossref, Google Scholar
• Tengs T. O. , Adams M. E. , Pliskin J. S. , Safran D. G. , Siegel J. E. , Weinstein M. C. , Graham J. D. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. (1995) 15 3 369 390 Crossref, Google Scholar
• Torrance G. W. Social preferences for health states: An empirical evaluation of three measurement techniques. Socioeconomic Planning Sci. (1976) 10 3 128 136 Google Scholar
• Torrance G. W. , Boyle M. H. , Horwood S. P. Application of multi-attribute utility theory to measure social preferences for health states. Oper. Res. (1982) 30 6 1043 1069 Link, Google Scholar
• Tsevat J. , Solzan J. G. , Kuntz K. M. , Ragland J. , Currier J. S. , Sell R. L. , Weinstein M. C. Health values of patients infected with human immunodeficiency virus. Medical Care (1996) 34 1 44 57 Crossref, Google Scholar
• US Public Health Service Task Force on Antipneumocystis Prophylaxis for Patients with Human Immunodeficiency Virus Infection Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. Morbidity and Mortality Weekly Report (1992) 41 RR-4 1 11 Google Scholar
• Volberding P. A. , Lagakos S. W. , Koch M. A. , Pettinelli C. , Myers M. W. , Booth D. K. , Balfour H. H. , Reichman R. C. , Bartlett J. A. , Hirsch M. S. Zidovudine in symptomatic human immunodeficiency virus infection: A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. New England J. Medicine (1990) 322 14 941 949 Crossref, Google Scholar
• Weinstein M. C. , Sloan F. A. From cost-effectiveness ratios to resource allocation: Where to draw the line? Valuing Health Care: Costs, Benefits, and the Effectiveness of Pharmaceuticals and Other Medical Technologies (1995) (Cambridge University Press, New York) Crossref, Google Scholar